摘要
目的分析雾化吸入不同剂量重组人干扰素α-2b治疗小儿病毒性肺炎效果。方法选择2017年6月至2018年6月郑州大学附属儿童医院治疗的202例小儿病毒性肺炎患儿为研究对象,现按照治疗方案不同分为对照组、低剂量组(A组)以及高剂量组(B组)。对照组应用常规治疗,A组应用小剂量干扰素α-2b,B组应用大剂量干扰素α-2b,比较三组患儿疗效,临床症状及临床体征消失时长,干预前后血清炎性因子水平。结果和对照组相比,A组以及B组治疗总有效率明显更高(P<0.05);和A组相比,B组患儿治疗总有效率明显更高(P<0.05)。与对照组相比,A组以及B组肺部湿啰音、憋喘以及咳嗽消失时长均明显更短(P<0.05);和A组相比,B组患儿的肺部湿啰音、憋喘以及咳嗽消失时长均明显更短(P<0.05)。干预前三组患儿的血清炎性因子水平差异无统计学意义(P>0.05);干预后受试者血清炎性因子水平均有所改善(P<0.05);干预后和对照组相比,A组以及B组血清炎性因子指标水平均更低(P<0.05),且B组血清炎性因子水平低于A组(P<0.05)。A组不良反应发生率低于B组(P<0.05)。结论应用高剂量重组人干扰素α-2b注射液对小儿病毒性肺炎患儿开展雾化治疗,够取得较为满意的成效,但高剂量用药不良反应发生风险较高,在对患儿开展临床治疗中,应当结合患儿耐受情况及其病情选择性地应用药物。
【Objective】To analyze the effect of different doses of recombinant human interferonα2 b in the treatment of viral pneumonia in children.【Methods】A total of 202 children with viral pneumonia treated in our hospital from June 2017 to June2018 were selected as the study objects.Now according to different treatment plans,they were divided into control group,low-dose group(group A)and high-dose group(group B).Routine treatment was used in the control group,low-dose interferonα2 b in group A and high-dose interferonα2 b in group B.The results were analyzed.【Results】Compared with the control group,the clinical efficacy of group A and group B was significantly better(P<0.05).Compared with group A,the treatment effect of group B was significantly better(P<0.05).There were significant differences in the disappearance time of lung moist rale,cough and suffocation among the three groups(P<0.05).Compared with group A,the disappearance time of lung moist rale,suffocation and cough in group B was significantly shorter(P<0.05).There was no significant difference in the level of serum inflammatory factors among the three groups before the intervention(P>0.05).Compared with the control group,the level of the above indexes in group A and group B was lower(P<0.05),the level of serum inflammatory factors in group B was lower than that in group A(P<0.05),and the incidence of adverse reactions in group A was lower than that in group B(P<0.05)【Conclusion】The application of high-dose recombinant human interferonα2 B injection in children with viral pneumonia has achieved satisfactory results.However,the adverse risk of high-dose drugs is high.In the clinical treatment of patients,we should combine their own tolerance and related conditions to selectively use drugs to treat diseases.
作者
熊蕾蕾
常会娟
王芳
靳秀红
XIONG Leilei;CHANG Huijuan;WANG Fang;JIN Xiuhong(Department of Respiration,Children's Hospital Affiliated to Zhengzhou University(Henan Children's Hospital,Zhengzhou Children's Hospital),Zhengzhou,Henan 450000,China)
出处
《中国医学工程》
2020年第11期57-60,共4页
China Medical Engineering
关键词
病毒性肺炎
干扰素Α-2B
雾化吸入
炎性因子
效果分析
pediatric pneumonia
interferonα2b
aerosol inhalation
inflammatory factors
efficacy analysis
